FOXO Technologies Inc. secures agreements to acquire preferred stock granting majority voting control in Ludwig Enterprises, Inc. The transaction strengthens FOXO’s position in the enterprise technology sector. Details on the financial terms or strategic rationale remain undisclosed.
Ludwig Enterprises secures a $250,000 convertible note and warrant financing from Alumni Capital. The agreement supports the company’s growth through structured debt and equity instruments. Details on terms or use of funds are not disclosed in the filing.
Ludwig Enterprises, Inc. names **Jose Antonio Reyes** as its **Interim Chief Executive Officer**, effective October 1, 2025. Reyes, currently the **Senior Head of Global Business Development**, previously led the company as CEO from August 2024 to April 2025. He retains his existing role while assuming interim executive responsibilities.
Ludwig Enterprises publishes an ASCO abstract describing a non-invasive breast cancer detection method. The approach uses mRNA analysis from cheek cells combined with machine learning to identify cancer signals. The research is presented ahead of the ASCO 2025 Annual Meeting.
Ludwig Enterprises introduces **Revealia Breast™**, a non-invasive cancer screening test using mRNA biomarker analysis from a cheek swab. The test represents the company’s first product in a pipeline of early-detection tools. It aims to simplify and enhance accessibility for breast cancer screening through minimal patient discomfort.
Ludwig Enterprises secures two abstracts in *Journal of Clinical Oncology*, highlighting research contributions in oncology. Marvin S. Hausman MD will present findings from a screening program at ASCO. The acceptance underscores Ludwig’s focus on advancing clinical oncology research.
Ludwig Enterprises Inc launches a non-invasive cancer diagnostics testing kit using AI-driven analysis of buccal (cheek) cells. The company partners with Dr. Kyle Ambert, former Director of Data Sciences at Nike, to develop the machine-learning-based diagnostic tool. This entry targets the rapidly growing AI-powered cancer screening market, leveraging Ludwig’s subsidiary M-RNA for Life.
Ludwig Enterprises names Scott Silverman as its new Chief Financial Officer. He will oversee financial operations under CEO Dr. Marvin S. Hausman. The company specializes in personalized diagnostics and therapeutics for diseases including cancer, diabetes, COPD, and heart disease.
Ludwig Enterprises, a genomics-focused company, plans to file a Non-Offering Prospectus in Q2 2023 to list on the Canadian Stock Exchange (CSE). The move aims to facilitate broader market access and liquidity for its shares. The company operates under the brand *Ludwig – The Genomics Language Company*™.